Market Closed -
Nasdaq
16:00:00 2024-06-21 EDT
|
5-day change
|
1st Jan Change
|
3.03
USD
|
-0.33%
|
|
+0.66%
|
-26.81%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
520.9
|
624.7
|
105
|
124.6
|
91.73
|
-
|
-
|
Enterprise Value (EV)
1 |
403.8
|
580.2
|
99.65
|
124.6
|
-67.53
|
2.429
|
-78.48
|
P/E ratio
|
-8.42
x
|
-3.15
x
|
-0.66
x
|
-1.26
x
|
-1.01
x
|
-1.18
x
|
-1.25
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1.91
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-1.63
x
|
EV / EBITDA
|
-6,637,221
x
|
-6,809,535
x
|
-617,990
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-14,519,678
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
4.96
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,242
|
27,726
|
30,099
|
30,099
|
30,174
|
-
|
-
|
Reference price
2 |
32.07
|
22.53
|
3.490
|
4.140
|
3.040
|
3.040
|
3.040
|
Announcement Date
|
3/23/21
|
3/23/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
48.07
|
EBITDA
|
-60.83
|
-85.21
|
-161.2
|
-
|
-
|
-
|
-
|
EBIT
1 |
-60.84
|
-125.7
|
-161.2
|
-103.7
|
-105.2
|
-138.7
|
-152.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-316.67%
|
Earnings before Tax (EBT)
1 |
-59.46
|
-125.8
|
-157
|
-98.79
|
-101.5
|
-133.5
|
-144.5
|
Net income
1 |
-59.46
|
-125.8
|
-157
|
-98.79
|
-101.7
|
-119.7
|
-126
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-262.12%
|
EPS
2 |
-3.810
|
-7.160
|
-5.300
|
-3.280
|
-3.008
|
-2.580
|
-2.428
|
Free Cash Flow
|
-27.81
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/21
|
3/23/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-34.18
|
-38.3
|
-45.51
|
-38.74
|
-38.7
|
-28.15
|
-26.03
|
-22.69
|
-26.83
|
-22.99
|
-26.1
|
-27.65
|
-30.2
|
-34.7
|
-38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-34.38
|
-39.75
|
-39.93
|
-39.42
|
-37.94
|
-26.32
|
-25.3
|
-22
|
-25.17
|
-21.83
|
-23.8
|
-26
|
-29.6
|
-33.1
|
-36.4
|
Net income
1 |
-34.38
|
-39.75
|
-39.93
|
-39.42
|
-37.94
|
-26.32
|
-25.3
|
-22
|
-25.17
|
-21.83
|
-24.8
|
-26
|
-29
|
-33.1
|
-36.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.800
|
-1.400
|
-1.330
|
-1.310
|
-1.260
|
-0.8700
|
-0.8400
|
-0.7300
|
-0.8400
|
-0.7200
|
-0.8275
|
-0.7825
|
-0.7175
|
-0.9400
|
-1.030
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/22
|
5/5/22
|
8/11/22
|
11/10/22
|
3/23/23
|
5/11/23
|
8/8/23
|
11/8/23
|
3/19/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
117
|
44.4
|
5.4
|
-
|
159
|
89.3
|
170
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-27.8
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.460
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/23/21
|
3/23/22
|
3/23/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
3.04
USD Average target price
10.62
USD Spread / Average Target +249.51% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.81% | 91.73M | | +15.19% | 122B | | +19.91% | 113B | | +8.24% | 22.84B | | -19.80% | 20.72B | | -16.19% | 16.51B | | -13.45% | 16.39B | | -44.35% | 15.83B | | +2.13% | 13.49B | | +66.67% | 11.67B |
Bio Therapeutic Drugs
|